

Original Research Article



Anti-inflammatory activity of 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid in LPS-induced rat model

Yudy Tjahjono^{a,1}, Srikanth Karnati^b, Kuncoro Foe^a, Efendi Anggara^a,
Yongky Novandi Gunawan^a, Hendy Wijaya^a, Steven^c, Handi Suyono^c, Senny Yesery Esar^a,
Wuryanto Hadinugroho^a, Hevi Wihadmadyatami^d, Süleyman Ergün^b,
Ratna Megawati Widharna^a, Caroline^{a,1,*}

^a Faculty of Pharmacy, Widya Mandala Catholic University Surabaya, Jalan Kalisari Selatan 1, Surabaya, 60237, East Java, Indonesia

^b Institute of Anatomy and Cell Biology, Julius-Maximilians-University Würzburg, Würzburg, Germany

^c Faculty of Medicine, Widya Mandala Catholic University Surabaya, Jalan Kalisari Selatan 1, Surabaya, 60237, East Java, Indonesia

^d Faculty of Veterinary Medicine, Universitas Gadjah Mada, Jalan Fauna 2, Sleman, 55281, Yogyakarta, Indonesia

ARTICLE INFO

Keywords:

Anti-inflammatory activity
2-((3-(Chloromethyl)benzoyl)oxy)benzoic acid
COX
LPS
Rat

ABSTRACT

Introduction: Salicylic acid derivate is very popular for its activity to suppress pain, fever, and inflammation. One of its derivatives is acetylsalicylic acid (ASA) which has been reported repeatedly that, as a non-steroidal anti-inflammatory drug (NSAID), it has a cardioprotective effect. Although ASA has various advantages, several studies have reported that it may induce severe peptic ulcer disease. We recently synthesized a new compound derived from salicylic acid, namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3-CH₂Cl) which still has the benefit of acetylsalicylic acid as an analgesic and antiplatelet, but lacks its harmful side effects (Caroline et al., 2019). In addition, *in silico* studies of 3-CH₂Cl showed a higher affinity towards protein receptor cyclooxygenase-2 (COX-2; PDB: 5F1A) than ASA. We hypothesized that 3-CH₂Cl inhibits the COX-2 activity which could presumably decrease the inflammatory responses. However, no knowledge is available on the anti-inflammatory response and molecular signaling of this new compound. Hence, in this study, we investigated the potential functional relevance of 3-CH₂Cl in regulating the inflammatory response in lipopolysaccharide (LPS)-induced rats. The results of this study show that this compound could significantly reduce the inflammatory parameter in LPS-induced rats.

Material and methods: Rats were induced with LPS of 0.5 mg/kg bw intravenously, prior oral administration with vehicle (3% *Pulvis Gummi Arabicum* / PGA), 500 mg/60 kg body weight (bw; rat dosage converted to human) of 3-CH₂Cl and ASA. The inflammatory parameters such as changes in the temperature of septic shock, cardiac blood plasma concentrations of IL-1 β and TNF- α (ELISA), blood inflammation parameters, white blood cell concentrations, and lung histopathology were observed. Meanwhile, the stability of 3-CH₂Cl powder was evaluated.

Result: After the administration of 500 mg/60 kg bw of 3-CH₂Cl (rat dosage converted to human) to LPS-induced rats, we observed a significant reduction of both TNF- α (5.70 \pm 1.04 \times 10³ pg/mL, p < 0.001) and IL-1 β (2.32 \pm 0.28 \times 10³ pg/mL, p < 0.001) cardiac blood plasma concentrations. Besides, we found a reduction of white blood cell concentration and the severity of lung injury in the 3-CH₂Cl group compared to the LPS-induced rat group. Additionally, this compound maintained the rat body temperature within normal limits during inflammation, preventing the rats to undergo septic shock, characterized by hypothermic (t = 120 min.) or hyperthermic (t = 360 min) conditions. Furthermore, 3-CH₂Cl was found to be stable until 3 years at 25 $^{\circ}$ C with a relative humidity of 75 \pm 5%.

Conclusion: 3-CH₂Cl compound inhibited inflammation in the LPS-induced inflammation response model in rats, hypothetically through binding to COX-2, and presumably inhibited LPS-induced NF- κ B signaling pathways. This study could be used as a preliminary hint to investigate the target molecular pathways of 3-CH₂Cl as a novel and

* Corresponding author.

E-mail address: caroline@ukwms.ac.id (Caroline).

¹ Authors contributed equally.

less toxic therapeutical agent in alleviating the COX-related inflammatory diseases, and most importantly to support the planning and development of clinical trial.

1. Introduction

Salicylic acid derivatives are widely known for their activity to suppress pain, fever, and inflammation. Acetylsalicylic acid (ASA) is one of those derivatives, which has been widely distributed commercially as a non-steroidal anti-inflammatory drug (NSAID) and thoroughly investigated [1]. In addition to the anti-inflammatory functions, it has been also reported to mediate anti-platelet function or cardioprotective properties [2], and improve bone regeneration particularly in osteoporotic conditions [3,4]. Furthermore, recent studies reported peroxisome proliferator-activated receptor alpha (PPAR α) served as a specific ASA-receptor mediating neuroprotective effect [5]. Although, ASA has various advantages, however, several studies have reported its harmful impact on the gastrointestinal tract, ranging from mild upper gastrointestinal problems to severe peptic ulcer disease [6–8].

Our group recently synthesized a new compound derived from salicylic acid, namely 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3-CH₂Cl) that has the benefits of acetylsalicylic acid but lacks its harmful side effects [9]. The analgesic and anti-platelet activity of 3-CH₂Cl was administered in normal Wistar rats. The data indicated that 3-CH₂Cl has a longer elimination half-life ($t_{1/2} = 39.4 \pm 3.9$ min) and higher C max (0.57 ± 0.02 μ g/mL) compared to ASA. These pharmacokinetic parameters showed that 3-CH₂Cl is widely and deeply distributed in all body tissues, yielding a slower onset of action and longer elimination time compared to ASA [9]. Moreover, our studies on *in vitro* human platelet aggregation studies postulated the mechanism of antiplatelet activity of 3-CH₂Cl, by inhibiting COX-1. Furthermore, *in silico* studies demonstrated a better affinity of 3-CH₂Cl for the COX2 receptor (PDB: 5F1A) than ASA [9]. Indeed, the COX-2 protein is predominantly induced by the main sources of prostaglandins (PGs) during inflammation [8]. Many researchers investigated the specific COX-2 mediated inflammatory responses, by administering endotoxin lipopolysaccharide (LPS) in various organs and tissues [10–12].

Lipopolysaccharide (LPS) is the outer membrane component of Gram-negative bacteria as the main pathogenic stimulator for severe infections (sepsis and acute lung injury) by inducing local and systemic inflammatory responses. The administration of LPS in healthy mice can activate LPS/TLR4 signal, inducing NF- κ B activation and the production of pro-inflammatory cytokines (IL-1 β and TNF- α) [13,14]. The observation of drug effects with animal models given LPS emphasizes changes in specific inflammatory parameters such as febrile septic shock and pulmonary edema [15,16].

Despite the novelty of 3-CH₂Cl, no data is available to explain the anti-inflammatory response, molecular signaling, and the stability study of this compound. Therefore as part of our continuous efforts to develop better anti-inflammatory agents and based on the above observations, in this study, we investigate the anti-inflammatory ability of 3-CH₂Cl by comparing the changes in LPS-induced specific inflammatory parameters, such as changes in temperature of septic shock, cardiac blood plasma IL-1 β and TNF- α concentrations, blood inflammation, cell concentration, and lung histopathology. The data generated in this study could be used as a preliminary guideline to investigate the target molecular pathways of 3-CH₂Cl as a therapeutical agent in alleviating the COX-related inflammatory diseases, and most importantly to support the planning and development of this compound as a new drug candidate in the clinical trial. Meanwhile, the stability of the material was evaluated to provide basic information for further material design. Finally, we confirmed the anti-inflammatory response of 3-CH₂Cl particularly by observing the significant reduction of cardiac blood plasma IL-1 β and TNF- α concentrations as well as other supporting parameters in LPS-induced rats treated with 3-CH₂Cl compared with untreated LPS-

induced rats and proposed the COX-2 and NF- κ B signaling pathways for the next level of studies.

2. Materials and methods

2.1. Chemical synthesis, characterization, and stability study

2-((3-(Chloromethyl)benzoyl)oxy)benzoic acid was synthesized in our laboratory as previously reported [9]. To observe the changes in chemical properties, we used Infrared (IR) Spectra Perkin Elmer System 60825 ranged from 4000 to 400 cm^{-1} (Perkin Elmer, Devon, UK) and High-Performance Liquid Chromatography (HPLC) Agilent 1220 Infinity LC G4288C HPLC systems (Agilent Technologies, California, USA). Additionally, we used Rheodyne 7725 100- μ L injector and Shimadzu Shim-pack VP-ODS 150 \times 4.6 mm (Shimadzu Corporation, Tokyo, Japan) as a stationary phase. Sample analysis was conducted isocratically using a mixture of methanol: phosphate buffer pH 4.0 (1:1, v/v) as a mobile phase with a flow rate of 1.0 mL/min. The KBF 720 climatic chamber binder (Binder GmbH, Tuttlingen, Germany) was used to store compounds at a constant condition.

2.2. Stability study

The stability study of 3CH₂Cl was conducted at a constant temperature ($40^{\circ} \pm 2^{\circ}\text{C}$) and 75 % \pm 5% relative humidity for six months, according to [17]. The compound was observed before and after six months of storage. Samples collected at 13 different time points were analyzed using HPLC to determine whether there are physicochemical changes observed during storage. The shelf-life of this compound was then determined using the previously reported validation method analysis [9], as % recovery (resulted in weight / theoretical weight \times 100 %).

2.3. Animal model

The experimental animals used in this study were 112 male *Rattus norvegicus* rats (3-month old, 150–200 grams (Pusvetma, Surabaya, Indonesia). Animals were housed in a temperature-controlled (21–25 $^{\circ}\text{C}$) room, with a 12-h light/dark cycle and they were allowed to consume food and drink *ad libitum* for 7 days. This study was approved by the University of Gadjah Mada Committee on the Use and Care of Animals No. 00050/04/LPPT/XI/2019. Healthy rats were measured at body temperatures between 37.2–38.5 $^{\circ}\text{C}$ [18] using a digital thermometer (Omron Healthcare, Singapore). In general, rats were divided into four groups, consisting of the vehicle/untreated control, LPS treated, LPS + ASA treated, and LPS+3-CH₂Cl treated groups. For cytokine concentration experiments, the animal groups were divided into more than four groups, due to different ASA and 3-CH₂Cl dosage applied (see below).

2.4. Lipopolysaccharide (LPS) treatment

Lyophilized powder of Lipopolysaccharide (LPS) isolated from Gram-negative of *Escherichia coli* type O111:B4 was diluted, yielding 0.5 mg/ml stock solution in 15 mM NaCl according to manufacturer's instruction (Sigma Aldrich, Saint Louis, USA). A single dose of LPS stock solution (0.5 mg/kg bw) was injected intravenously through the tail vein for 30 min, subsequently followed by drug administration orally.

2.5. Acetylsalicylic acid (ASA) and 2-((3-(chloromethyl)benzoyl)oxy)benzoic acid (3-CH₂Cl) dosage administration

Pure acetylsalicylic acid (Labtech Citra Persada, Surabaya, Indonesia) was diluted by 3% *Pulvis Gummi Arabicum* (PGA) (Pharmalab, Bandung, Indonesia) suspension. 3-CH₂Cl was synthesized as previously described [9], and diluted by 3% PGA suspension. Following the injection of LPS, each dose of diluted ASA (LPS + ASA) and 3-CH₂Cl (LPS+3-CH₂Cl) compounds was orally administered to the animals. The cytokine concentration assay was then performed (see below). The doses administered to rats were 10.33; 51.65; 93.00; 134.33; and 175.67 mg/kg body weight. The drug dosages were calculated according to the previous conversion method [19], representing 100; 500; 900; 1300; and 1700 mg/60 kg bw as the usual dose of drug treatment in human, respectively. Each experimental group consisted of six animals (n = 6) according to Federer's minimum required number of experimental designs [20] with a minor addition.

In another experimental setup, the white blood cells (WBC) cell blood count, temperature, and histological examinations were performed following the administration of ASA and 3-CH₂Cl at a single dose of 10.33 mg/200 g bw (equivalent to 500 mg/60 kg bw) to a pre-determined group of rats that had been treated by LPS. The ASA and 3-CH₂Cl were administered orally at the first hour and the sixth hour after LPS injection. The control group (untreated rats) was injected with 15 mM NaCl (PT Widarta Bakti, Surabaya, Indonesia) intravenously and subsequently followed by the oral administration of 2 ml of 3% PGA. In this experiment, each group consisted of ten animals (n = 10), following Federer's minimum required number of experimental designs [20].

2.6. Blood preparation for WBC count and cytokine TNF- α and IL-1 β concentrations assay

Plasma for cytokine testing was obtained from the blood via intracardiac and collected on microtubes containing EDTA (500 mM). The microtube was centrifuged for 15 min at 1000 rpm. The supernatant containing blood plasma was collected in a tube and stored at -4 °C, for further cytokine testing.

In another experimental group, rat blood was collected (according to the previous method), 24 h after the oral administration of ASA, 3-CH₂Cl, or control. A small amount of pure blood was taken to determine the concentrations of leukocytes, monocytes, granulocytes, and lymphocytes (Automatic Hematology Analyzer Horiba, USA). This analysis focused on the number of WBC cells in rats by administering LPS with ASA/3-CH₂Cl (10.33 mg/200 g bw).

2.7. Cytokine TNF- α and IL-1 β concentrations assay

TNF- α and IL-1 β cytokines were tested using the Enzyme-linked immunosorbent assay kit (ELISA, Elabscience, Wuhan, China). Rat blood plasma was diluted with 500 mM EDTA (1:2, v/v) and incubated in a coated ELISA 96-er tube. The extracellular TNF- α and IL-1 β concentrations were analyzed by color change (Multiskan GO microplate spectrophotometer, Thermo Scientific, Vantaa, Finland). Cytokine concentrations were determined using optical density (OD) regression and GraphPad Prism Software v.7 as a standard.

2.8. Temperature measurement assay

The rectal temperature of each animal in each group was measured periodically with a digital thermometer (Omron Healthcare, Singapore). The initial temperature (T₀: 37.2–38.5 °C) was the temperature of rats following adaptation for 30 min at 24–26 °C [18]. The observation of temperature changes was carried out every 60 min for 600 min. The time point was symbolized as T_n. Whereas "n" stands for 60 min (T₆₀), 120 min (T₁₂₀), and with subsequent addition in 60 min intervals, until it reaches the maximal time point 600 min (T₆₀₀). The temperature




Fig. 1. Administration of 3-CH₂Cl lowered cytokine TNF- α and IL-1 β concentrations in the LPS-treated rat model.

Effect of 500 mg/60 kg bw of 3-CH₂Cl as well as ASA on plasma TNF- α (A) and IL-1 β (B) levels in LPS-induced rats (n = 6), showing a significant reduction of both cytokines concentration compared with the control group (+LPS + vehicle). Blood samples were collected after LPS + ASA and LPS+3-CH₂Cl administration as presented in the method section. Results were expressed as mean \pm standard deviation (SD), and statistical significance was shown as ***P < 0.001.

changes (Δ T) were calculated as changes in the body temperature of each animal at each measurement time interval against the initial temperature.

2.9. Histopathology study

The rats' lungs were dissected after drug administration, temperature measurements, and euthanasia. The lung organs were fixed with 10 % formalin solution, dehydrated with alcohol-xylene, and immersed in paraffin before cutting the tissue. All tissue sections were stained with hematoxylin-eosin. Lung injury was observed microscopically at 10 randomly selected spots. The observation scores were determined according to the observation of pulmonary edema, as follows: normal = 0; perivascular edema = 1; peribronchial edema, interstitial edema, perivascular cell infiltration = 2; alveolar edema, interstitial cell infiltration = 3; and alveolar cell infiltration = 4 [21].

2.10. Statistical evaluation

Statistical analysis was performed using *post-hoc*-dunnet test and *p* values less than 0.05 were considered statistically significant. The data subsets were graphically presented using GraphPad Prism Software v.7. Unless others mentioned, all of the data related to 3-CH₂Cl animal groups were compared with the positive control (LPS + Vehicle groups).




Fig. 2. Administration of 3-CH₂Cl reduced rectal temperature of LPS-treated rat hyperthermic model. LPS-treated rat group displayed a typical septic shock as a response to 0.5 mg/kg bw of LPS, indicated by the hypothermic condition at the nadir of T120 and hyperthermic condition at T360. The changes in rectal temperature following the administration of ASA (500 mg/60 kg bw) and 3-CH₂Cl (500 mg/60 kg bw) in LPS-treated rats are shown in the graphic. Results were expressed as mean ± standard deviation (SD), and statistical significance compared with + LPS/Vehicle was shown as *P < 0.05 or **P < 0.01. “Ns” or without asterisks indicated as non-significant.

3. Results

3.1. 3-CH₂Cl exerts anti-inflammatory activity by a significant reduction of cardiac blood plasma cytokine TNF-α and IL-1β concentrations in LPS-treated rat model

To assess the degree of inflammation through humoral components,

we observed the cardiac blood plasma cytokine concentration of LPS-induced rats, particularly pro-inflammatory TNF-α and IL-1β (Fig. 1). The TNF-α and IL-1β levels were significantly increased in LPS-treated rats, and decreased in LPS + ASA treated and LPS+3-CH₂Cl treated groups (see also supplementary Fig. 2). We observed significant reduction of both TNF-α and IL-1β cytokines, particularly following the treatment of LPS-induced rats with 500 mg/60 kg bw of ASA (TNF-α




Fig. 3. Administration of 3-CH₂Cl reduced differential white blood cells count in the LPS-treated rat model. The number of leukocytes (A) as well as monocytes (B), lymphocytes (C), and granulocytes (D) increased in LPS-treated rats groups (n = 10) compared with the control group -LPS + vehicle. After administration of LPS + ASA (500 mg/60 kg bw) and 3-CH₂Cl (500 mg/60 kg bw), the blood cells count decreased and it was shown that 3-CH₂Cl had a good effect as ASA. Results were expressed as mean ± standard deviation (SD), and statistical significance was shown as “ns” P > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, or ****P < 0.0001.





Fig. 4. Administration of 3-CH₂Cl reduced lung edema in the LPS-treated rat model. Representative histological sections from the experimental group (n = 10) showed acute lung injury, characterized by lung edema, intra-alveolar hemorrhage, and interstitial cell infiltration in the + LPS + vehicle group (B) compared with the control group -LPS + vehicle (A). The administration of the dose of 500 mg/60 kg bw of ASA (C) and particularly with 500 mg/60 kg bw of 3-CH₂Cl in intravenous LPS-injected rats exhibited lesser lung injury (D). Lung injury score was shown (E) as the mean ± standard deviation (SD).



4.97±/1.07 × 10³ pg/mL, p<0.001; IL-1β 2.01±/0.33 × 10³ pg/mL, p<0.001) or 3-CH₂Cl (TNF-α 5.70±/1.04 × 10³ pg/mL, p<0.001); IL-1β 2.32±/0.28 × 10³ pg/mL, p<0.001). We found no dose-dependent decrement of TNF-α and IL-1β levels in the LPS+3-CH₂Cl treated group. The cytokine level in LPS + ASA treated animal group decreased after treatment with 100 mg/60 kg bw and 500 mg/60 kg bw of ASA and increased again at other dosages greater than 500 mg/60 kg bw. The highest cytokine levels were observed in the LPS treated animal group and LPS + ASA treated animal group (1700 mg/60 kg bw of ASA). Although the concentration of cytokines in the LPS+3-CH₂Cl treated

group was positioned approximately at the same level, a subtle elevated cytokine level was observed in the 3-CH₂Cl treated animal group (1300 mg/60 kg bw of 3-CH₂Cl). Taken together, we observed the significant reduction of cardiac blood plasma TNF-α and IL-1β in 3-CH₂Cl treated animal groups particularly following the treatment of LPS-induced rats with 500 mg/60 kg bw compound dosage.




Fig. 5. A fingerprint of the 3-CH₂Cl compound.

(A) Patterns of 3-CH₂Cl infrared spectroscopy on day-0 (red) and day-185 (black) showed an identical pattern. (B) HPLC pattern of a typical 3-CH₂Cl compound. A small graphic indicates a salicylic acid pattern as a precursor compound. No impurities were detected.

3.2. 3-CH₂Cl exerts an anti-pyrogenic effect by reducing the rectal temperature of LPS-treated rat hyperthermic model

To measure the anti-pyrogenic activity of the compounds in endotoxin LPS-treated animals, we observed the mean temperature difference (ΔT) for 10 h in the 60-min interval, with T₀ was defined as the starting point, when the animal was intravenously injected by a single dose of 0.5 mg/kg bw of LPS. As shown in Fig. 2, the rats displayed typical septic shock in response to a single dose of 0.5 mg/kg bw of LPS (+LPS vehicle group), indicated by hypothermic condition (negative ΔT), particularly at T₆₀ and T₁₂₀. The rectal temperature difference began to rise 240–300 min after the LPS injection and reached its peak value at about 360 min, interpreted as a hyperthermic condition. The rectal temperature remained elevated until the end of the observation. In the LPS+3-CH₂Cl group, the rectal temperature was relatively stable from T₀ until the first 3-CH₂Cl oral administration at T₆₀ min. No significant differences were observed in comparison with its basal normal temperature until T₁₈₀. It began to rise slightly at 240–360 minutes observation point, and gradually decreased again following the second oral administration of 500 mg/60 kg bw of 3-CH₂Cl at T₃₆₀, until reaching its basal temperature at T₆₀₀. However, in LPS + ASA treated group, the animals showed no hypothermic response following LPS injection. It began to rise about 60 min after the first oral administration of

500 mg/60 kg bw of ASA. In contrast to the LPS treated group, the LPS + ASA group exhibited a slight hyperthermic condition with the maximum temperature difference (ΔT) reaching $+0,55 \pm 0,22$ °C. The temperature began to decrease gradually and fell rapidly after the second oral administration of ASA. It reached the basal normal temperature at T₄₈₀ until the end of the observation. Taken together, animals treated with the 3-CH₂Cl group shows relatively stable temperature from T₀ until T₆₀₀. Now significant hypothermic and hyperthermic conditions were observed within the 3-CH₂Cl treated group.

3.3. 3-CH₂Cl suppresses the immune cells and therefore exerts anti-inflammatory properties by decreasing the cardiac white blood cell concentration in LPS-induced rats

To investigate whether 3-CH₂Cl could suppress the immune cells in LPS-treated rats, we measured the number of absolute leukocytes (Fig. 3A), lymphocytes (Fig. 3B), monocytes (Fig. 3C), and granulocytes (Fig. 3D) in isolated whole blood. Twenty-four hours after LPS treatment with additional repeated doses (two times) of oral administration of the salicylic acid compound in between, the animals were euthanized and the blood cells were counted immediately. We observed a significant increase of all WBCs differential counts, with the highest WBCs concentration observed in all LPS-injected rat groups, followed by LPS +

ASA and LPS+3-CH₂Cl groups. The untreated rats showed the lowest WBCs concentration. In leukocytes and lymphocytes parameters, a very low blood cell concentration was observed. Additionally, the leukocytes and lymphocytes parameters observed in the LPS+3-CH₂Cl group were slightly lower than those observed in the LPS + ASA group, suggesting the alleviated suppression of immune cells mediated by 3-CH₂Cl compared with ASA.

3.4. Administration of 3-CH₂Cl reduce LPS induced acute lung injury

To analyze the direct impact of the salicylic acid-derived compound on lessening the typical acute lung injury 24 h after LPS administration, we performed the microscopic histological analysis with a scoring system. Representative histological sections from all experimental groups were presented in Fig. 4A–D. The normal untreated rat group (Fig. 4A) showed relatively clear alveolar spaces and indicated no infiltration of immune cells. In contrast, the lung of LPS-treated animal groups (Fig. 4B) exhibited intra-alveolar edema, massive cell infiltration, and hemorrhage. Following the administration of 500 mg/60 kg bw of ASA in the LPS-injected rat group (Fig. 4C), we observed a significant reduction of cell infiltrates and alveolar edema. Meanwhile, the administration of 500 mg/60 kg bw of 3-CH₂Cl (Fig. 4D) could reduce the degree of lung injury better than ASA, indicated visually by slightly bigger intra-alveolar space. To have a better analysis of the observation statistically, we converted the visual interpretation into the numeric score and presented the data in graphical lung injury scores (Fig. 4E). Indeed, the highest score indicating severely damaged lungs was significantly demonstrated in LPS treated animal groups (3.125 ± 0.39). On the other hand, a slight lung injury score was demonstrated in LPS + ASA and 3-CH₂Cl group summary.

3.5. The 3-CH₂Cl powder is stable until 3 years at 25°C with a relative humidity of 75 ± 5%

The Physico-Chemical characteristics of 3-CH₂Cl were white powder and odorless. Following storage at $40^\circ \pm 2^\circ\text{C}/75\% \pm 5\% \text{RH}$ for 6 months, the recovery percentages of this compound at 13 different sampling points can be seen in Supplementary Table 1. This compound was found to be stable, as shown in the HPLC chromatogram and IR spectroscopy results (Fig. 5), by comparing the results before and after storage for 6 months (Fig. 5a). Besides, there was no additional peak attributed to salicylic acid in the HPLC chromatogram (Fig. 5b), indicating no chemical degradation observed until the end of the stability study. Through theoretical conversion according to ICH guidelines, the 3-CH₂Cl powder is stable until 3 years at 25°C with a relative humidity of $75 \pm 5\%$.

4. Discussion

It has been previously reported that salicylic acid and its derivate ASA prevent inflammation in part by enzyme cyclooxygenase inhibition. Besides, salicylic acid and its derivate ASA could prevent inflammation by their specific inhibition of IKK- β , preventing the activation of NF- κ B and thereby significantly suppress genes involved in the pathogenesis of inflammatory response such as cytokines [22]. Although, ASA as an anti-inflammatory agent has various advantages, however, its harmful impact on the gastrointestinal tract motivated our research group to investigate the anti-inflammatory property of a novel and less toxic salicylic acid derived 3-CH₂Cl as another therapeutic drug in the LPS-induced rat model.

LPS-administration in rodents has been used frequently to study the inflammatory response, specific organ failure, and its typical physiological changes [23]. LPS could bind to its receptor in Toll-like receptor 4 (TLR4)-dependent pathway, and stimulate the cytokine through the Mitogen-activated protein kinase (MAPK) and nuclear factor kappa beta (NF- κ B) routes, which may activate several immunological responses

[13], particularly cytokines transcription, and therefore may cause severe inner organ injury, such as typical LPS-generated acute lung injury (ALI). Although the application of LPS-induced inflammation response model in rats exerts various differences compared with humans, there are several similarities which have been reported, in the inflammatory responses to LPS between rodents and human. Therefore this method is still reliable for preliminary investigation of the inflammation response [24], as carried out for the anti-inflammatory study of potential 3-CH₂Cl in the pre-clinical phase. In addition to our previously reported *in silico* docking results which showed that 3-CH₂Cl could act as a potential COX-2 ligand [9,25], the above-mentioned signal transduction led us towards another hypothesis of the 3-CH₂Cl mechanism of action, which might have the similar pathway with ASA.

The pro-inflammatory cytokines concentration plays a pivotal role, particularly in the investigation of the drug's effectiveness to inhibit LPS-induced inflammation. TNF- α and IL-1 β are widely known as a representative of pro-inflammatory cytokines and have been widely used as a peripheral marker, particularly because of the association with its transcription factor, NF- κ B. Indeed, our data in Fig. 1 did support this hypothesis by the specific reduction of rat TNF- α and IL-1 β cardiac blood plasma concentrations following the oral administration of 500 mg/60 kg bw of 3-CH₂Cl in LPS-induced systemic inflammation rats. This may indicate that this compound might exert anti-inflammatory molecular pathways properties through NF- κ B signaling. To investigate the dose-dependent effect, we evaluated the cytokine concentration following the administration of salicylic acid derivate in five increment concentrations. Interestingly, we found the dose-dependent decrement of both plasma cytokine TNF- α and IL-1 β concentrations, ranging from 100–500 mg/60 kg bw with the nadir was reached by 500 mg/60 kg bw. The preliminary findings pointed towards the similar anti-inflammatory effect of 3-CH₂Cl compared with ASA, particularly at the dose of 500 mg/60 kg bw. Therefore to simplify the overall experimental design due to limited resources, we focused on the observation of other anti-inflammatory parameters following 500 mg/60 kg bw dosage administration only. Other physiological changes following the reduction of the pro-inflammatory cytokine, such as isothermic antipyretic effect, immune cell depletion, and the reduction of organ damage severity, are expected after 500 mg/60 kg bw dose of 3-CH₂Cl administration compared with vehicle-administered LPS-rats.

It is known that after LPS-administration, typical leukopenia is observed in the first 1–4 h examination, followed by a rebound leukocytosis in a zenith of 12–24 h after LPS injection. This is indicated as IL-6 stimulated neutrophilia to increase the survival of neutrophils during the acute inflammatory condition [26]. Therefore to reproduce a contrast result of 3-CH₂Cl action in white blood cell concentration of LPS-treated animals group, we used the 24-h time point as our starting analysis. A significant increase in white blood cell concentration was observed in LPS-treated animals (Fig. 3), this is in agreement with [27]. The administration of 500 mg/60 kg bw of 3-CH₂Cl in LPS-animals could reduce the white blood cell concentration. This phenomenon could also be seen in ASA treated animals group, indicating the anti-inflammatory action of 3-CH₂Cl and ASA to inhibit neutrophilia, particularly 24 h post endotoxin LPS injection.

In terms of temperature changes, LPS generated fevers commonly polyphasic [28], and may vary depending on multiple methodological factors such as dose and laboratory ambient. During the initial phase of intravenous LPS injection, the animals show typical septic shock hypothermia and are subsequently followed by the hyperthermia phase [15]. Those typical polyphasic temperatures during systemic inflammation are triggered mainly by cyclooxygenase isoforms and maintained particularly in the brain [29]. As expected, our results in Fig. 2 support hypothetical arguments of 3-CH₂Cl potential inhibitory ligands namely COX-2. In comparison to LPS-treated rats, the dose administration of 500 mg/60 kg bw of 3-CH₂Cl could stabilize the rat's body temperature, preventing them to undergo polyphasic hypothermic and hyperthermic conditions. The hyperthermic prevention of 3-CH₂Cl may indicate that




Fig. 6. Oral administration of 3-CH₂Cl in intravenous LPS-treated rat model exhibited anti-inflammatory activity.

(A) Classical LPS-induced inflammatory pathways at the cellular level: TLR-4 signal transduction. (B) 3-CH₂Cl decreased the production of TNF-α and IL-1β pro-inflammatory cytokines, decreased the white blood cell concentration, and reduced the severity of lung injury, presumably through IKK and NF-κβ signaling pathways. 3-CH₂Cl had an antipyretic property due to binding on its hypothetical receptor, COX-2 (C).

this compound could have antipyretic properties. Following the administration of 3-CH₂Cl, this compound may block the COX-2 activity and thus inhibit hyperthermia during systemic inflammation.

As mentioned before, besides the polyphasic thermal character, intravenous LPS administration could induce severe acute lung injury (ALI) through histologically observed massive infiltration of the inflammatory cell causing pulmonary edema, which is triggered by the generation of reactive oxygen species (ROS), increased cytokine responses, MAPK activation, NF-κβ expression, and its associated molecules [16]. As expected, severe ALI was demonstrated in the typical histological section of LPS-treated rat lungs (Fig. 4A), as well as its associated scoring data (Fig. 4B) 24 h post LPS injection. Additionally, we demonstrated that 3-CH₂Cl treatment could reduce partially the severity of ALI, better than ASA. Even though the effect of 3-CH₂Cl has not been well studied at the molecular level in the context of inflammatory cascades, these histological findings supported our general observational study, namely the anti-inflammatory of 3-CH₂Cl which may cause the inhibition of immunological signal during inflammation, as well as decrease the immune cell concentration and its cytokine response. For the next aim of studies, investigation of reactive oxygen species (ROS) production and cyclooxygenase inhibition in the presence of 3-CH₂Cl would strengthen the preclinical observation of this compound in inhibiting inflammation.

Meanwhile, to complete the previously reported physicochemical characterization of 3-CH₂Cl [9], in this study we observed the stability of this compound based on storage time and humidity parameters. Our data as shown in Fig. 5A with additional HPLC pattern (Fig. 5B) indicated that 3-CH₂Cl was still stable after 6 months of storage in 40 ± 2°C with a relative humidity of 75 ± 5%. No chemical degradation was observed. In other words, according to Q1A(R2) Stability Testing Method of New Material and Drug Product guidelines, this compound could be stored and used for various testing until 3 years at 25°C with a relative humidity of 75 ± 5%, without making an extra effort to

synthesize a new 3-CH₂Cl compound.

In summary (Fig. 6), our results showed that 3-CH₂Cl oral administration in intravenous LPS-treated rat model exhibited anti-inflammatory activity, particularly through decreased TNF-α and IL-1β pro-inflammatory cytokines, decreased white blood cell concentration, and reduced severity of lung injury. These results led to a better characterization of 3-CH₂Cl as a potential anti-inflammatory drug, particularly focusing on investigating the cyclooxygenases and NF-κβ signaling pathways. The compound, 3-CH₂Cl could also stabilize the rat's body temperature during the inflammatory conditions, preventing the rats to undergo hyperthermic condition, and thus, it exhibited antipyretic activity. Additionally, 3-CH₂Cl was found to be stable until 3 years at 25°C with a relative humidity of 75 ± 5%. Taken together, this paper pointed towards the hypothetical mechanism of 3-CH₂Cl as a therapeutic agent in alleviating COX-related inflammatory diseases. The results could support the planning and development of 3-CH₂Cl in the preclinical and clinical trials.

Authors contribution

Yudy Tjahjono and Caroline designed the experiments, carried out experiments, analyzed the data, and prepared the manuscript. Efendi Anggara and Yongky Novandi carried out the experiments and analyzed the data. Srikanth Karnati, Kuncoro Foe, Hendy Wijaya, Steven, Handi Suyono, Senny Yesery Esar, Wuryanto Hadinugroho, Hevi Wihadmadyatami, Süleyman Ergün, and Ratna Megawati Widharna assisted the experiments and analyzed the data.

Funding

The work was supported by the following grants: Research and Community Service Institute of Widya Mandala Catholic University, Surabaya, Indonesia (954a/WM01.5/N/2018 to Yudy Tjahjono) and Ministry of Research, Technology and Higher Education of the Republic of Indonesia (115w/WM01.5/N/2018 to Kuncoro Foe).

Acknowledgements

We would like to thank Mr. Arnold Sulistyio Cionander, Mr. Ignasius Agyo Palmado, Ms. Siti Surdijati, Ms. Helen Kristiana Budi Agung, and Ms. Wiska Stephani Tjiali (Faculty of Pharmacy, Widya Mandala Catholic University, Surabaya) for fruitful discussion.

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:<https://doi.org/10.1016/j.prostaglandins.2021.106549>.

References

- [1] J.R. Vane, R.M. Botting, The mechanism of action of aspirin, *Thromb. Res.* 110 (5-6) (2003) 255–258, [https://doi.org/10.1016/S0049-3848\(03\)00379-7](https://doi.org/10.1016/S0049-3848(03)00379-7).
- [2] A. Lanas, L.A. Garcia-Rodriguez, M.T. Arroyo, F. Gomollon, F. Feu, A.G. Perez, E. Zapata, G. Bastida, L. Rodrigo, S. Santolaria, M. Guell, C.M. de Argila, E. Quintero, F. Borda, J.M. Pique, Risk of upper gastrointestinal ulcer bleeding associated with selective NF-κβ-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations, *BMJ J.* 55 (2006) 1731–1738, <https://doi.org/10.1136/gut.2005.080754>.
- [3] Y. Liu, S. Fang, X. Li, J. Feng, J. Du, L. Guo, Y. Su, J. Zhou, G. Ding, Y. Bai, S. Wang, H. Wang, Aspirin inhibits LPS-induced macrophage activation via the NF-κB pathway, *Sci. Rep.* 7 (1) (2017), 11549, <https://doi.org/10.1038/s41598-017-10720-4>.
- [4] Y. Yue, K. Xie, L. Xie, Y. Deng, Endowing polyetheretherketone with anti-inflammatory ability and improved osteogenic ability, *J. Biomater. Sci. Polym. Ed.* (2020) 1–19, <https://doi.org/10.1080/09205063.2020.1815634>.
- [5] D.R. Patel, A. Roy, K. Pahan, PPARα serves as a new receptor of aspirin for neuroprotection, *J. Neurosci. Res.* 98 (4) (2019) 626–631, <https://doi.org/10.1002/jnr.24561>.

- [6] B. Cryer, K.W. Mahaffey, Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment, *J. Multidiscip. Healthc.* 7 (2014) 137–146, <https://doi.org/10.2147/JMDH.S54324>.
- [7] V.E. Valkhoff, M.C. Sturkenboom, E.J. Kuipers, Risk factors for gastrointestinal bleeding associated with low-dose aspirin, *Best Pract. Res. Clin. Gastroenterol.* 26 (2) (2012) 125–140, <https://doi.org/10.1016/j.bpg.2012.01.011>.
- [8] J.R. Vane, Y.S. Bakhle, R.M. Botting, Cyclooxygenases 1. and 2, *Annu. Rev. Pharmacol. Toxicol.* 38 (1998) 97–120, <https://doi.org/10.1146/annurev.pharmtox.38.1.97>.
- [9] Caroline, K. Foe, S.Y. Esar, A. Soewandi, H. Wihadmadyatami, R.M. Widharna, W. D. Tamayanti, E. Kasih, Y. Tjahjono, Evaluation of analgesic and antiplatelet activity of 2-(3 (chloromethyl)benzoyloxy)benzoic acid, *Prostaglandins Other Lipid Mediat.* 145 (2019) 1–8, <https://doi.org/10.1016/j.prostaglandins.2019.106364>.
- [10] A. Waage, A. Halstensen, T. Espevik, Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease, *Lancet* 329 (8529) (1987) 355–357, [https://doi.org/10.1016/S0140-6736\(87\)91728-4](https://doi.org/10.1016/S0140-6736(87)91728-4).
- [11] V. Nikoui, S. Mehrzadi, M.I. Khan, W. Aman, S. Ostadhadi, A.R. Dehpour, Licofelone, a dual cyclooxygenase/5-lipoxygenase inhibitor, reverses endotoxin-induced impaired atrial chronotropic responsiveness to cholinergic stimulation in rats, *Eur. J. Pharmacol.* (2020), 173569, <https://doi.org/10.1016/j.ejphar.2020.173569>.
- [12] X. Shen, C. Weng, Y. Wang, C. Wang, S. Feng, X. Li, H. Li, H. Jiang, H. Wang, J. Chen, Lipopolysaccharide-induced podocyte injury is regulated by calcineurin/NFAT and TLR4/MyD88/NF- κ B signaling pathways through angiopoietin-like protein 4, *Genes Dis.* (2020), <https://doi.org/10.1016/j.gendis.2020.07.005>.
- [13] J.Q. Wang, Y.S. Jeelall, L.L. Ferguson, K. Horikawa, Toll-like receptors and cancer: MYD88 mutation and inflammation, *Front. Immunol.* 5 (367) (2014) 1–10, <https://doi.org/10.3389/fimmu.2014.00367>.
- [14] P.J. Barner, M. Karin, Transcription factor in chronic, *N. Engl. J. Med.* 336 (15) (1997) 1066–1071, <https://doi.org/10.1056/NEJM199704103361506>.
- [15] M.D. Dogan, H. Ataoglu, E.S. Akarsu, Effects of different serotypes of *Escherichia coli* lipopolysaccharides on body temperature in rats, *Life Sci.* 67 (19) (2000) 2319–2329, [https://doi.org/10.1016/S0024-3205\(00\)00821-3](https://doi.org/10.1016/S0024-3205(00)00821-3).
- [16] H. Vaez, M. Najafi, N.S. Toutounchi, J. Barar, A. Barzegar, G. Alireza, Metformin alleviates lipopolysaccharide-induced acute lung injury through suppressing toll-like receptor 4 signaling, *iranian journal of allergy, asthma, Immunology* 15 (2016) 498–507.
- [17] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Q1A (R2) Guideline, Stability Testing of New Drug Substances and Drug Products, 2021. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q1-r2-stability-testing-new-drug-substances-products-step-5_en.pdf (Accessed on 26 August 2020).
- [18] E. Briese, Normal body temperature of rats: the setpoint controversy, *Neurosci. Biobehav. Rev.* 22 (3) (1998) 427–436, [https://doi.org/10.1016/S0149-7634\(97\)00051-1](https://doi.org/10.1016/S0149-7634(97)00051-1).
- [19] A.B. Nair, S. Jacob, A simple practice guide for dose conversion between animals and human, *J. Basic Clin. Pharm.* 7 (2) (2016) 27–31, <https://doi.org/10.4103/0976-0105.177703>.
- [20] W.T. Federer, *Experimental Design, Theory and Application*, Oxford and IBH Publ. Co, New Delhi, 1967.
- [21] C.F. Chian, C.H. Chiang, Y.J. Chu, C.H. Chuang, S.L. Liu, Y.H. Jheng, H. Zhang, J. H. Ryu, Apocynin attenuates lipopolysaccharide-induced lung injury in an isolated and perfused rat lung model, *Shock* 38 (2) (2012) 196–202, <https://doi.org/10.1097/SHK.0b013e31825a1982>.
- [22] M. Yin, Y. Yamamoto, R. Gaynor, The anti-inflammatory agents aspirin and salicylate inhibit the activity of I κ B kinase- β , *Nature* 396 (1998) 77–80, <https://doi.org/10.1038/23948>.
- [23] P.P.S.J. Khedoe, S. Kleijn, A.M. Oeveren-Rietdijk, J.J. Plomp, H.C. Boer, M. Pel, P. C.N. Rensen, J.F.P. Berbee, P.S. Hiemstra, Acute and chronic effects of treatment with mesenchymal stromal cells on LPS-induced pulmonary inflammation, emphysema and atherosclerosis development, *PLoS One* 12 (9) (2017) 1–21, <https://doi.org/10.1371/journal.pone.0183741>.
- [24] S.J. Foster, L.M. McCormick, B.A. Ntolosi, D. Campbell, Production of TNF α by LPS-stimulated murine, rat and human blood and its pharmacological modulation, *Agents Actions* 38 (1993) C77–C79, <https://doi.org/10.1007/BF01991143>.
- [25] W.D. Tamayanti, R.M. Widharna, Caroline, B. Soekarjo, Uji Aktivitas Analgesik Asam 2-(3-(Klorometil)Benzoiloksi)Benzoat dan Asam 2-(4-(Klorometil) Benzoiloksi)Benzoat pada Tikus Wistar Jantan dengan Metode Plantar Test, *Jurnal Farmasi Sains dan Komunitas* 13 (1) (2016) 15–22, <https://doi.org/10.24071/jpsc.131125>.
- [26] G. Cox, J. Gaudie, Interleukin-6, in: D.G. Remick, J.S. Friedland (Eds.), *Cytokines in Health and Disease*, Marcel Dekker, New York, NY, 1997, pp. 81–99.
- [27] E. Tavares, F.J. Miñano, R. Maldonado, M.J. Dascombe, Endotoxin fever in granulocytopenic rats: evidence that brain cyclooxygenase-2 is more important than circulating prostaglandin E $_2$, *J. Leukoc. Biol.* 80 (6) (2006) 1375–1387, <https://doi.org/10.1189/jlb.0106064>.
- [28] A.Y. Rudaya, A.A. Steiner, J.R. Robbins, A.S. Dragic, A.A. Romanovsky, Thermoregulatory responses to lipopolysaccharide in the mouse: dependence on the dose and ambient temperature, *Am. J. Physiol. Regulat. Integr. Compar. Physiol.* 289 (5) (2005) R1244–R1252, <https://doi.org/10.1152/ajpregu.00370.2005>.
- [29] A. Blomqvist, D. Engblom, Neural mechanisms of inflammation induced fever, *Neuroscientist* 24 (4) (2018) 1–19, <https://doi.org/10.1177/1073858418760481>.